Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT ) 6.020 +0.080 (+1.35%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Sagimet Biosciences Inc. - Series A Common Stock < Previous 1 2 3 Next > This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday November 12, 2024 Via Benzinga Sagimet Biosciences to Participate in the UBS Global Healthcare Conference November 07, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH November 01, 2024 Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. Via Investor's Business Daily Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 October 29, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024 October 16, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology October 11, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session October 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 01, 2024 Via Benzinga Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH October 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit September 12, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Participate in Two Upcoming Investor Conferences September 04, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024 August 14, 2024 SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 14, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors August 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat June 10, 2024 Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET From Sagimet Biosciences Inc. Via GlobeNewswire What's Going On With Sagimet Biosciences Stock On Thursday? June 06, 2024 Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress. Via Benzinga Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 June 06, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? June 05, 2024 Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... Via Benzinga Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday May 16, 2024 Via Benzinga Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 May 16, 2024 Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH From Sagimet Biosciences Inc. Via GlobeNewswire SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 May 15, 2024 SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates May 15, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 May 07, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer May 06, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 April 22, 2024 Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat March 27, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session March 25, 2024 Via Benzinga Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors March 25, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
